Author: claimsbot

1. A method for providing direct bonding of wires to silicon for microelectronics and microelectromechanical systems (MEMS), said method comprising:
preparing a rough pothole during one of the many deep etch steps already performed in microelectronics and MEMS fabrication;
roughening of the smooth silicon surface in and around said rough pothole; and
plastically deforming a ball-bond into said rough pothole, such that the interconnection will eliminate a costly metallization layer, and thereby lower fabrication expenses and enable further high temperature processing.
2. The method according to claim 1, wherein the metallization layer eliminated is a gold layer.
3. The method according to claim 1, wherein the metallization layer eliminated is an aluminum layer.
4. The method according to claim 1, wherein the method is part of semiconductor device fabrication.
5. The method according to claim 4, wherein said fabrication uses passivation layers.
6. The method according to claim 5, wherein the passivation layers are used as hard masks.
7. The method according to claim 5, wherein the passivation layers are used as electric isolation.
8. The method according to claim 1, wherein said pothole is a silicon Deep Reactive Ion Etching (DRIE) pothole.
9. A system for providing direct bonding of wires to silicon for microelectronics and microelectromechanical systems (MEMS), said system comprising:
means for preparing a rough pothole during one of the many deep etch steps already performed in microelectronics and MEMS fabrication;
means for roughening of the smooth silicon surface in and around said rough pothole; and
means for plastically deforming a ball-bond into said rough pothole, such that the interconnection will eliminate a costly metallization layer, and thereby lower fabrication expenses and enable further high temperature processing.
10. The system according to claim 9, wherein the metallization layer eliminated is a gold layer.
11. The method according to claim 1, wherein the metallization layer eliminated is an aluminum layer.
12. The system according to claim 9, wherein the system is part of semiconductor device fabrication.
13. The system according to claim 12, wherein said fabrication uses passivation layers.
14. The system according to claim 13, wherein the passivation layers are used as hard masks.
15. The system according to claim 13, wherein the passivation layers are used as electric isolation.
16. The system according to claim 9, wherein said pothole is a silicon Deep Reactive Ion Etching (DRIE) pothole.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An apparatus comprising: a coherent light source; a first diffraction grating, the first diffraction grating having a first period; a micro-electrical mechanical system (MEMS), the MEMS being displaced from the first diffraction grating and being configured to modulate and induce a phase shift in light received from the coherent light source; an analyte recognition material disposed on the surface of the first diffraction grating; and a detector configured to receive light from the coherent light source after the light has been diffracted from the first diffraction grating and modulated by the MEMS.
2. The apparatus of claim 1, wherein the MEMS is configured to simulate a lateral displacement of a grating with respect to a normal of the first grating.
3. The apparatus of claim 2, wherein the lateral displacement is a displacement of less than one period.
4. The apparatus of claim 3, wherein the lateral displacement is a displacement of approximately \xbc period.
5. The apparatus of claim 1, further comprising: a spatial filter disposed relative to the MEMS such that predetermined orders of diffracted light are prevented from reaching the detector.
6. The apparatus of claim 1, wherein the MEMS is configured to modulate the light at a frequency of approximately 1 kHz or more.
7. The apparatus of claim 1, wherein the MEMS is configured to modulate the light at a frequency of approximately 10 kHz or more.
8. The apparatus of claim 1, wherein the analyte recognition material is one of an antibody, antigen, peptide, nucleic acid, cell, phage display, protein, lectin, molecular imprinted polymer (MIP), fellerene, carbon nanotube, and a carbon-based nano-system.
9. The apparatus of claim 1, the detector being a first detector, the apparatus further comprising: a light source, the light source being configured to excite a fluorescent marker thereby causing spontaneous emission from the fluorescent marker; a second detector, the second detector being configured to receive energy from the spontaneous emission.
10. A method for examining light, comprising: illuminating a first grating with light from a coherent light source, the first grating including an analyte recognition material deposited thereon; receiving the light from the coherent light source at a micro-electrical mechanical system (MEMS) after the light passes through the grating including the analyte recognition material; modulating the light received at the MEMS at a frequency; and detecting a phase of the light received from the MEMS at a detector.
11. The method of claim 10, wherein the MEMS is configured to modulate the light at a frequency of approximately 1 kHz or more.
12. The method of claim 10, wherein the MEMS is configured to modulate the light at a frequency of approximately 10 kHz or more.
13. The method of claim 10, wherein the MEMS is configured to simulate a lateral displacement of a grating with respect to the first grating.
14. The method of claim 13, wherein the lateral displacement is approximately (\xbc) period.
15. The method of claim 10, wherein detecting a phase of the light received from the MEMS at a detector includes detecting a phase change of the light due to a binding event.

1. A compound represented by Formula I:
or a pharmaceutically acceptable salt thereof, wherein
X is C\u2014CN;
Cy is
z is hetaryl, \u2014C1-6alkyl-O\u2014C1-6alkyl-, \u2014C0-6alkyl-(heterocyclyl), \u2014C0-6alkyl-(hetaryl), \u2014C(O)\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-O\u2014C1-6alkyl-O\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl)-C(O)\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014C0-6alkyl, \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), or \u2014S(O)2\u2014(hetaryl), wherein any of the alkyl, heterocyclyl, or hetaryl optionally is substituted with 1-6 independent halo, OH, \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), or \u2014C0-6alkyl;
in which the wavy bond is the point of attachment, and wherein the piperazine or morpholine moieties are optionally substituted with 1-6 independent C0-6alkyl groups;
Y is \u2014C(C0-6alkyl)(C0-6alkyl)-, \u2014N(C0-6alkyl)-, \u2014N(C0-6alkyl)-C1-6alkyl-, O, S, >N\u2014C2-6alkyl-N\u2014(C0-6alkyl)(C0-6alkyl), >N\u2014C2-6alkyl-O\u2014C0-6alkyl, >N\u2014C1-6alkyl-C(O)\u2014NH\u2014C0-6alkyl, or >N\u2014C2-6alkyl-N\u2014C(O)\u2014C1-6alkyl; and
R1 is aryl, hetaryl, or heterocyclyl, optionally substituted with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, \u2014C3-10cycloalkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), \u2014C1-6alkyl-C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN, OH, \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), or C0-6alkyl; or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Cy is
3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is aryl optionally substituted with with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the aryl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo or C0-6alkyl.
4. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is aryl optionally substituted with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, \u2014C3-10cycloalkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), \u2014C1-6alkyl-C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN, OH, \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), or C6alkyl.
5. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hetaryl optionally substituted with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the hetaryl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo or C0-6alkyl.
6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is hetaryl optionally substituted with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, \u2014C3-10cycloalkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), \u2014C1-6alkyl-C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN, OH, \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), or C0-6alkyl.
7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is heterocyclyl optionally substituted with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo or C0-6alkyl.
8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is heterocyclyl optionally substituted with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, \u2014C3-10cycloalkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), \u2014C1-6alkyl-C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN, OH, \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), or C0-6alkyl.
9. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Y\u2014R1 is
10. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Y is \u2014N(C0-6alkyl)-.
11. A compound represented by Formula I:
a pharmaceutically acceptable salt thereof, wherein
X is C\u2014CN;
Cy is
Z is hetaryl, \u2014C1-6alkyl-O\u2014C1-6alkyl-, \u2014C0-6alkyl-(heterocyclyl), \u2014C0-6alkyl-(hetaryl), \u2014C(O)\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-O\u2014C1-6alkyl-O\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl)-C(O)\u2014C0-6alkyl, \u2014C(O)\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014C0-6alkyl, \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), or \u2014S(O)2\u2014(hetaryl), wherein any of the alkyl, heterocyclyl, or hetaryl optionally is substituted with 1-6 independent halo, OH, \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), or \u2014C0-6alkyl;
or z is
in which the wavy bond is the point of attachment, and wherein the piperazine or morpholine moieties are optionally substituted with 1-6 independent C0-6alkyl groups;
Y is \u2014C(C0-6alkyl)(C0-6alkyl)-, \u2014N(C0-6alkyl)-, \u2014N(C0-6alkyl)-C1-6alkyl-, O, S, >N\u2014C2-6alkyl-N\u2014(C0-6alkyl)(C0-6alkyl), >N\u2014C2-6alkyl-O\u2014C0-6alkyl, >N\u2014C1-6alkyl-C(O)\u2014NH\u2014C0-6alkyl, or >N\u2014C2-6alkyl-N\u2014C(O)\u2014C1-6alkyl;
wherein R1 is selected from the following table:
12. A compound represented by Formula I:
or a pharmaceutically acceptable salt thereof, wherein
X is C\u2014CN;
Cy is
Y is \u2014C(C0-6alkyl)(C0-6alkyl)-, \u2014N(C0-6alkyl)-, \u2014N(C0-6alkyl)-C1-6alkyl-, O, S, >N\u2014C2-6alkyl-N\u2014(C0-6alkyl)(C0-6alkyl), >N\u2014C2-6alkyl-O\u2014C0-6alkyl, >N\u2014C1-6alkyl-C(O)\u2014NH\u2014C0-6alkyl, or >N\u2014C2-6alkyl-N\u2014C(O)\u2014C1-6alkyl; and
R1 is aryl, hetaryl, or heterocyclyl, optionally substituted with 1-6 independent halo, \u2014CN, \u2014OH, \u2014C0-6alkyl, \u2014C3-10cycloalkyl, -haloC1-6alkyl, \u2014C2-6alkynyl, \u2014N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), \u2014C1-6alkyl-C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(heterocyclyl), \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014O\u2014C0-6alkyl-(hetaryl), \u2014S(O)2\u2014N(C0-6alkyl)(C0-6alkyl), aryl, hetaryl, or heterocyclyl substituents, or substituted with an oxo (\u2550O) using a bond from the aryl, hetaryl, or heterocyclyl ring, wherein any of the substituents optionally is substituted with 1-6 independent halo, CN, OH, \u2014C0-6alkyl-O\u2014C0-6alkyl, \u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-N(C0-6alkyl)(C0-6alkyl), \u2014C(O)\u2014C0-6alkyl-(heterocyclyl), or C0-6alkyl;
wherein z is selected from the following table:
13. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Y\u2014R1 is
14. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An image capture apparatus comprising:
an image sensor which outputs an image;
a moving picture image recording instruction unit which issues a first instruction for recording the image obtained by the image sensor as a moving picture image;
a still picture image recording instruction unit which issues a second instruction for recording the image obtained by the image sensor as a still picture image;
a change instruction unit which issues a third instruction for changing a magnification of the image while recording the image as a moving picture image; and
a cancel unit which invalidates the first instruction during a period when the magnification of the image is being changed.
2. The image capture apparatus according to claim 1, further comprising:
an end detection unit which detects an end of changing the magnification of the image; and
a control unit which validates the first instruction when the end detection unit detects the end of changing.
3. The image capture apparatus according to claim 2, further comprising:
a count unit which counts a predetermined time after the end of changing the magnification of the image; and wherein
the control unit validates the first instruction after the count unit has counted the predetermined time.
4. The image capture apparatus according to claim 2, further comprising:
a still picture image recording unit which records the image as a still picture image when the first instruction is issued.
5. The image capture apparatus according to claim 4, further comprising:
a recording instruction detection unit which detects the second instruction during recording of the image as a still picture image by the still picture image recording unit; and
a moving picture image recording unit which records the image after the recording of the image as a still picture image by the still picture image recording unit is completed, when the first instruction is issued.
6. The image capture apparatus according to claim 1, further comprising:
a lens which forms an image on the image sensor;
a driving unit which drives the lens;
an operation control unit which controls operation of the driving unit in accordance with the third instruction;
a sensing unit which senses an operating state of the driving unit; and
a determining unit which determines whether or not the magnification of the image is changed based on the operating state of the driving unit sensed by the sensing unit.
7. An image capture method comprising steps of:
issuing a first instruction for recording an image obtained by an image sensor as a moving picture image;
issuing a second instruction for recording the image obtained by the image sensor as a still picture image;
issuing a third instruction for changing a magnification of the image while recording the image as a moving picture image; and
invalidating the first instruction during a period when the magnification of the image is being changed.
8. The image capture method according to claim 7, further comprising steps of:
detecting an end of changing the magnification of the image; and
validating the first instruction when the end of changing is detected.
9. The image capture method according to claim 8, further comprising steps of:
counting a predetermined time after the end of changing the magnification of the image; and wherein the first instruction is validated after the count unit has counted the predetermined time.
10. The image capture method according to claim 8, further comprising steps of:
recording the image as a still picture image when the first instruction is issued.
11. The image capture method according to claim 10, further comprising steps of:
detecting the second instruction during recording of the image as a still picture image; and
recording the image after the recording of the image as a still picture image is completed, when the first instruction is issued.
12. A computer program product configured to store program instructions for execution on a computer system enabling the computer system to perform:
issuing a first instruction for recording an image obtained by an image sensor as a moving picture image;
issuing a second instruction for recording the image obtained by the image sensor as a still picture image;
issuing a third instruction for changing a magnification of the image while recording the image as a moving picture image; and
invalidating the first instruction during a period when the magnification of the image is being changed.
13. The computer program product according to claim 12, enabling the computer system to further perform:
detecting an end of changing the magnification of the image; and
validating the first instruction when the end of changing is detected.
14. The computer program product according to claim 13, enabling the computer system to further perform:
counting a predetermined time after the end of changing the magnification of the image; and wherein the first instruction is validated after the count unit has counted the predetermined time.
15. The computer program product according to claim 13, enabling the computer system to further perform:
recording the image as a still picture image when the first instruction is issued.
16. The computer program product according to claim 15, enabling the computer system to further perform:
detecting the second instruction during recording of the image as a still picture image; and
recording the image after the recording of the image as a still picture image is completed, when the first instruction is issued.
17. An image capture apparatus comprising:
means for outputting an image;
a moving picture image recording instruction means for issuing a first instruction for recording the image obtained by the image outputting means as a moving picture image;
a still picture image recording instruction means for issuing a second instruction for recording the image obtained by the image outputting means as a still picture image;
a change instruction means for issuing a third instruction for changing a magnification of the image while recording the image as a moving picture image; and
a cancel means for invalidating the first instruction during a period when the magnification of the image is being changed.
18. The image capture apparatus according to claim 17, further comprising:
an end detection means for detecting an end of changing the magnification of the image; and
a control means for validating the first instruction when the end detection means detects the end of changing.